AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04546165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital inhibition plus exercise
Description: Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
Study NCT04546165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
Study NCT01628601 — intervention group
Intervention type: DRUG
Intervention: Fixed combination 0.3 mg bimatoprost and 5 mg timolol
Description: Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
Study NCT00101114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT00101114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC
Study NCT00101114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT00537407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
Study NCT00537407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets
Study NCT02049619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharyngeal pack
Description: Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
Study NCT00038779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Study NCT03096873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
Study NCT01656226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eryfotona AK-NMSC® cream
Description: Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
Study NCT01656226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen SPF 50+
Description: Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
Study NCT02411929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unlabeled ertugliflozin for oral use
Description: 15 mg oral (3 x 5 mg tablets)
Study NCT02411929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14^C-labeled ertugliflozin for IV use
Description: 100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Study NCT02411929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14^C-labeled ertugliflozin for oral use
Description: 100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Study NCT03343600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 100 mg/tablet, 2 tablets daily
Study NCT01349491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
Study NCT01349491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
Study NCT03844581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Description: Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
Study NCT03844581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propiverine Hydrochloride
Description: propiverine hydrochloride 20 mg/once per day in the morning
Study NCT03343600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos 2 tablets daily
Study NCT02544997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: 12mg P.O. for 2wks q21days
Study NCT05102968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based rehabilitation supporting with the mobile application
Description: For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
Study NCT05102968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised rehabilitation by the therapist
Description: For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
Study NCT02249533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot Light Concussion App
Description: Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
Study NCT00540345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
Study NCT03958708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
Study NCT00540345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
Study NCT00084149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate, Lamivudine, and Zidovudine
Description: antiretroviral therapy
Study NCT00084149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: antiretroviral therapy
Study NCT03407885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled payments for knee and hip replacement
Description: The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices.
Study NCT01639755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new texture shaped breast implants
Description: breast implant surgery
Study NCT04408911 — intervention group
Intervention type: DRUG
Intervention: Midazolam vs. Lormetazepam
Description: In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
Study NCT00575874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone HCl
Description: 0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Study NCT00575874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Study NCT00575874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Study NCT00575874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 30 mg capsules once daily for 12 weeks
Study NCT00575874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching tablets or capsule once daily for 12 weeks
Study NCT03847909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
Study NCT03847909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
Study NCT00348894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: \[S,S\]-reboxetine
Study NCT00348894 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Any
Description: Any standard of care treatment for DPN
Study NCT01856621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus and charcoal
Description: 2 inhalations as a single dose
Study NCT02216630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem Cell (ADSC) Therapy
Description: Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
Study NCT00540345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study NCT00540345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
Study NCT03911895 — intervention group
Intervention type: DEVICE
Intervention: Stent more than 26 mn length
Description: stent length in patients undergoing PCI (Drug Eluting Stent)
Study NCT03911895 — intervention group
Intervention type: DEVICE
Intervention: Stent equal to or less than26 mn length
Description: stent length in patients undergoing PCI (Drug Eluting Stent)
Study NCT00527943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
Study NCT00527943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
Study NCT03973775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Cream 5%
Description: Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
Study NCT03973775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Cream 5%
Description: Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
Study NCT00188513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conformal intensity modulated radiotherapy (IMRT)
Study NCT03329495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMA-orientated right hemicoloectomy
Description: Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
Study NCT03329495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMV-orientated right hemicoloectomy
Description: Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
Study NCT01707953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
Study NCT01707953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to mimic midodrine
Study NCT02345967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 100 Sensor
Description: One Model 100 Sensor to be implanted per subject.
Study NCT02497027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing report released to physician at 4 weeks post enrollment
Study NCT02497027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing report released to physician at 12 weeks post enrollment
Study NCT02250443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338 (Bimagrumab)
Study NCT01893073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful walking program
Study NCT01742741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
Study NCT02373020 — intervention group
Intervention type: OTHER
Intervention: colonoscopic biopsies
Study NCT01888146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain program
Description: Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
Study NCT03670303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures
Study NCT01643993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hCG at the Time of Embryo Transfer
Description: hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
Study NCT01643993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
Study NCT00208962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy and blood stem cell transplantation
Description: A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
Study NCT00629499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
Study NCT00629499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 of IV cyclophosphamide
Study NCT00629499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
Study NCT02260726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study NCT01393808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 1-month Paricalcitol 2mcg/day
Study NCT01393808 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1-month Placebo Treatment
Study NCT03063476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-13 labeled Lysine
Description: Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
Study NCT03063476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
Study NCT06326073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Treatment
Description: Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
Study NCT01856621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 2 inhalations as a single dose
Study NCT01856621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler and charcoal
Description: 2 inhalations as a single dose
Study NCT01856621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler
Description: 2 inhalations as a single dose
Study NCT02260726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Study NCT02260726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT00758641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-PRP Injection
Description: L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
Study NCT00758641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: kenacort 40 mg/ml triamcinolon acetonide
Study NCT04570189 — intervention group
Intervention type: DEVICE
Intervention: Auscul-X
Description: The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
Study NCT04463004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavrilimumab
Description: Treatment infusion
Study NCT04463004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo infusion
Study NCT01531413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen Insufflation
Description: At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen